Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A647057-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $750.90 | |
A647057-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,200.90 |
Synonyms | SCHEMBL1613533 | 1254698-46-8 | Alicapistat | HY-109001 | ABT-957 | Alicapistat [INN] | BWF3F50KF8 | (2R)-1-Benzyl-N-((2RS)-4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl)-5-oxopyrrolidine-2-carboxamide | 1-benzyl-N-(4-(cyclopropylamino)-3,4-dioxo-1-ph |
---|---|
Specifications & Purity | ≥98% |
Biochemical and Physiological Mechanisms | Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD). Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC 5 |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD) Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC 50 value of 395 nM . In Vitro Alicapistat exihibits inadequate CNS-penetration concentrations to obtain a pharmacodynamic effect. Calpain 1 (µ-calpain) and 2 (m-calpain) expression in a calcium-dependent manner with µ-molar or m-molar calcium concentrations required for their respective activation, respectively.\nAlicapistat (compound 22) (100 nM) prevents Aβ oligomer-induced deficits in synaptic transmission in rat. Alicapistat (compound 22) (385 nM) displays efficacy with respect to prevention of NMDA-induced neurodegeneration and A-induced synaptic dysfunction in rat hippocampal slice cultures. Alicapistat (9-21 nM) has the CSF concentrations without reaching the IC 50 for calpain inhibition and shows no dose-limiting toxicities (DLTs) in the broad populations studies. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Alicapistat (compound 22) (iv or po; 1-3 mg/kg) shows moderate mean plasma clearance values (CLp) in mouse, rat, and dog (0.13-1.04 L/hr.kg), while high in monkey (1.98 L/hr.kg). Mean steady-state volume of distribution values (Vss) were moderate in mouse, dog, and monkey (0.64-1.8 L/kg), but higher in rat (3.4 L/kg). The plasma elimination half-life (t 1/2 ) was shortest in dog (1.7 hours), followed by 2.3 hours in monkey and approximately 6.0 hours in mouse and rat. Oral bioavailability (F) values were high in mouse, rat, and dog (>80%), while moderate in monkey (14%). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 395 nM (Human calpains 1) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2R)-1-benzyl-N-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-5-oxopyrrolidine-2-carboxamide |
---|---|
INCHI | InChI=1S/C25H27N3O4/c29-22-14-13-21(28(22)16-18-9-5-2-6-10-18)24(31)27-20(15-17-7-3-1-4-8-17)23(30)25(32)26-19-11-12-19/h1-10,19-21H,11-16H2,(H,26,32)(H,27,31)/t20?,21-/m1/s1 |
InChi Key | MMLDHJRGTZHNHV-BPGUCPLFSA-N |
Canonical SMILES | C1CC1NC(=O)C(=O)C(CC2=CC=CC=C2)NC(=O)C3CCC(=O)N3CC4=CC=CC=C4 |
Isomeric SMILES | C1CC(=O)N([C@H]1C(=O)NC(CC2=CC=CC=C2)C(=O)C(=O)NC3CC3)CC4=CC=CC=C4 |
Alternate CAS | 1254698-46-8 |
PubChem CID | 67095330 |
MeSH Entry Terms | 1-benzyl-N-(4-(cyclopropylamino)-3,4-dioxo-1-phenyl-2-butanyl)-5-oxo-D-prolinamide;2-pyrrolidinecarboxamide, N-(3-(cyclopropylamino)-2,3-dioxo-1-(phenylmethyl)propyl)-5-oxo-1-(phenylmethyl)-, (2R)-;ABT-957;alicapistat |
Molecular Weight | 433.50 |
Enter Lot Number to search for COA:
Solubility | DMSO : 50 mg/mL (115.34 mM; ultrasonic and warming and heat to 60°C) |
---|